Communiqués Johnson & Johnson Berne S.E.

Actions

000943981

US4781601046

Cours en clôture Berne S.E. Autres places de cotation 00:00:00 26/06/2024			Varia. 5j.	Varia. 1 janv.
131,3 ^CHF	-1,17%		+1,93%	-0,07%

24/06	La Cour suprême des États-Unis donne aux entreprises pharmaceutiques une chance de contrecarrer les poursuites pour financement du terrorisme	RE
24/06	J&J : 50M d'élèves aidés via le programme 'Sight for Kids'	CF

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Johnson & Johnson Reaches 50 Million Children Through Sight For Kids Program	25/06	AQ
Johnson & Johnson completes acquisition of Proteologix, Inc.	24/06	AQ
Johnson & Johnson Completes Acquisition of Proteologix, Inc.	21/06	BU
Health Authority Warns of Brain Risks From Pseudoephedrine Medications	21/06	AQ
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease	20/06	PR
More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme	20/06	BU
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction	20/06	PR
Johnson & Johnson - Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer	18/06	AQ
Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products	17/06	BU
J&J commits five-year investment in Italian medicine manufacturing	17/06	AQ
Johnson & Johnson - Late-breaking results show nipocalimab significantly improves Sjogren's disease activity in a Phase 2 study	17/06	AQ
Johnson & Johnson - TALVEY demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma	17/06	AQ
Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study	15/06	PR
Johnson & Johnson : Findings from landmark RESONATE 2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first line chronic lymphocytic leukaemia treatment with up to 10 years follow up	14/06	PU
Johnson & Johnson : Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed duration IMBRUVICA® (ibrutinib) plus venetoclax as first line treatment for patients with chronic lymphocytic leukaemia, including those with high risk disease	14/06	PU
That's Stentertainment	13/06	AQ
Johnson & Johnson : to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference Press Release	12/06	PU
Talc Plaintiffs File Motion for Temporary Restraining Order to Limit Johnson & Johnson’s Use of Bankruptcy Strategy	12/06	BU
Johnson & Johnson agrees to pay $700M to settle talcum lawsuit with dozens of states	12/06	AQ
Johnson & Johnson : to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference Transcript	12/06	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Joseph Wolk, CFO de J&J: Perte d'exclusivité de son médicament phare

Le 23 janvier 2024 à 18:30